R
Recursion Pharma
Biotech & Life Sciences · Salt Lake City, United States · Founded 2013 · IPO 2021
Investors
32 investors on Recursion Pharma's cap table
Sourced from Dealroom's funding history. Investor profile links are shown where available.
Recursion Pharma mafia
Startups founded by Recursion Pharma alumni
Former Recursion Pharma employees who went on to start their own companies. Sorted by Dealroom signal score.
Joe Betts-LacroixUnited States
Viswa ColluruUnited States
Ron Alfa, MD, PhDUnited States
Zavain DarUnited States
David KartchnerUnited States
Dean Y. LiUnited States
Karthik Raman, PhDUnited States
Ian QuigleyUnited States
Daniel CohenCanadaGlobal footprint
Where Recursion Pharma has talent and traffic
team presence
across markets
Talent graph
The shape of Recursion Pharma's talent
Dealroom maps Recursion Pharma's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.
Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.
Patent intelligence
$23M patent portfolio · 117 active families
Where Recursion Pharma concentrates vs peers
Each axis is a top-10 topic across Recursion Pharma and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Capital deployed
Recursion Pharma's 5 investments and acquisitions.
Every disclosed deal where Recursion Pharma appeared as a backer or acquirer, 2020–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Recursion Pharma's capital deployment.
Where the deals concentrate by sector, stage, and decade.
01 · Deployment strategy vs peers
Where Recursion Pharma deploys vs peers
Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.
02 · Portfolio market map
Recursion Pharma's portfolio, mapped.
Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.
Market sentiment
What the market is saying about Recursion Pharma
An AI-synthesized read of the highest-engagement posts about Recursion Pharma on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Recursion Pharma on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.